Retrospective Study of Drug Response in 87 Patients with Progressive Supranuclear Palsy

Nieforth, Keith; Golbe, Lawrence I.

doi:10.1097/00002826-199308000-00006

Cited by 92 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only few patients experienced benefit from anticholinergics or amantadine. The initial positive response to L -dopa administration in PSP has ranged from 18 [36] to 51% [38, 39] in different studies. When combined with anticholinergics, dopamine agonists, amantadine or selegiline a higher (60%) benefit has been reported [22].…”

Section: Discussionmentioning

confidence: 99%

“…A small review of 12 patients with pathologically proven PSP concluded that use of L -dopa, dopamine agonists, amantadine, tricyclic antidepressants, anticholinergic agents and selective serotonin-reuptake inhibitors was largely ineffective and frequently associated with side effects [40]. Nevertheless, many neurologists believe that trials of amantadine and amitriptyline are worthwhile, since they may benefit some patients [39, 41]. Treatment with antiparkinsonian medication offers some improvement of symptoms in PSP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors

Papapetropoulos

Gonzalez

Mash³

2005

Eur Neurol

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP) is the second most common parkinsonian syndrome, characterized by a ‘diverse’ clinical phenotype. Although several different diagnostic guidelines have been proposed, the early and accurate diagnosis of PSP remains problematic and neuropathology is still considered the ‘gold standard’. In order to contribute to the better clinical characterization of PSP, we conducted a postmortem study in a cohort of 22 consecutive PSP brain donors and compared our results with those of previously published reports. Our results further demonstrate and expand the varied clinical picture of PSP. Furthermore, we report associations between older age at onset, early dementia, early falls and smoking with shorter PSP duration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors

Papapetropoulos

Gonzalez

Mash³

2005

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…Tricyclic antidepressants improved gait and rigidity in three of four patients in a small double-blind trial 40 , on the other hand, these drugs have a high risk/benefit ratio in population with PSP, according to a published review 41 . In spite of this, nortryptiline seems to be useful as an option for depression in this population, but it lacks randomized controlled data that support this observation 42 .…”

Section: Symptomatic Treatmentmentioning

confidence: 99%

Progressive supranuclear palsy: new concepts

Barsottini

Felı́cio

Aquino

et al. 2010

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia. PSP is defined neuropathologically by the accumulation of neurofibrillary tangles in the subthalamic nucleus, pallidum, red nucleus, substantia nigra, striatum, pontine tegmentum, oculomotor nucleus, medulla and dentate nucleus. Over the last decade many lines of investigations have helped refine PSP in many aspects and it is the purpose of this review to help neurologists identify PSP, to better understand its pathophysiology and to provide a more focused, symptom-based treatment approach. Key words: progressive supranuclear palsy, atypical parkinsonism, tauopathy.Paralisia supranuclear progressiva: conceitos atuais RESUMO A paralisia supranuclear progressiva (PSP) é uma doença neurodegenerativa, que afeta principalmente o tronco cerebral e os núcleos da base. O quadro clínico se caracteriza por oftalmoparesia supranuclear, instabilidade postural e demência . Do ponto de vista anátomo-patológico, a PSP se caracteriza por acúmulo de emaranhados neurofibrilares no núcleo subtalâmico, globo pálido, núcleo rubro, substância negra, estriado, tegumento da ponte, núcleos oculomotores, bulbo e núcleo denteado. Nas últimas décadas, muitas linhas de pesquisa têm colaborado para redefinir a PSP em muitos aspectos. Os objetivos dessa revisão são auxiliar o neurologista geral na identificação da doença, compreensão da sua fisiopatologia, além de apresentar alternativas para seu tratamento sintomático. Palavras-chave: paralisia supranuclear progressiva, parkinsonismo atípico, taupatias.

show abstract

“…Op grond van de motorsymptomen worden antiParkinsonmiddelen gegeven; echter, ondanks hoge doseringen, zelden succesvol. 18 Omdat er een verlaagde GABA-receptoren in de frontale cortex zijn aangetoond is er één studie uitgevoerd met de GABA-agonist zolpidem. In deze dubbelblinde studie (n=10) werd een significante verbetering geconstateerd in de verticale oogbewegingen en in de motore functies.…”

Section: Behandeling En Prognoseunclassified

Progressieve Supranucleaire Verlamming. Interventie middels acetylcholineesteraseremmer?

Nijboer

Dautzenberg²

2009

GEEG

View full text Add to dashboard Cite

Progressive supranucleair palsy (PSP) is a serious neurologic disease which is seldom diagnosed due to its complexity. In 1996 international diagnostic criteria were developed by a group of experts, the diagnosis remains complicated. We describe three cases, which were followed in the period 2001-2008. In these case reports we elaborate on the therapeutic use of rivastigmine. During off-label rivastigmine use, patients showed minimal further cognitive decline, specifically with respect to frontal defects. However, larger studies and trials are necessary to explore the effects of rivastigmine in patients with PSP.

show abstract

Retrospective Study of Drug Response in 87 Patients with Progressive Supranuclear Palsy

Cited by 92 publications

References 0 publications

Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors

Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors

Progressive supranuclear palsy: new concepts

Progressieve Supranucleaire Verlamming. Interventie middels acetylcholineesteraseremmer?

Contact Info

Product

Resources

About